Article
Immunology
Changfang Fu, Yu Liu, Xinghua Han, Yueyin Pan, Hong-qiang Wang, Hongzhi Wang, Haiming Dai, Wulin Yang
Summary: A 25-gene signature classifier was developed to effectively predict pathologic complete response to paclitaxel and anthracycline-based neoadjuvant chemotherapy in breast cancer. The classifier showed good predictive ability for different schemes and was significantly correlated with immune characteristics. Immune-related biological processes enriched in the genes of the signature suggest an active involvement of the immune ecosystem in modulating clinical response.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Soo-Yeon Kim, Nariya Cho, Yunhee Choi, Su Hyun Lee, Su Min Ha, Eun Sil Kim, Jung Min Chang, Woo Kyung Moon
Summary: A nomogram incorporating MRI and clinical-pathologic variables was developed to predict pathologic complete response after neoadjuvant chemotherapy in breast cancer. The nomogram showed good discrimination and calibration abilities, effectively identifying independent variables associated with pCR.
Article
Oncology
Li-Yun Xie, Kun Wang, Hai-Lu Chen, Yan-Xia Shi, Yuan-Qi Zhang, Hao-Yu Lin, Yuan-Ke Liang, Ying-Sheng Xiao, Zhi-Yong Wu, Zhong-Yu Yuan, Si-Qi Qiu
Summary: The study identified clinical T stage, clinical N stage, and tumor expression of ALDH3A2 as potential markers for predicting tumor recurrence in patients who achieved a tumor pCR after NAC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Zijian Zhou, Beatriz E. Adrada, Rosalind P. Candelaria, Nabil A. Elshafeey, Medine Boge, Rania M. Mohamed, Sanaz Pashapoor, Jia Sun, Zhan Xu, Bikash Panthi, Jong Bum Son, Mary S. Guirguis, Miral M. Patel, Gary J. Whitman, Tanya W. Moseley, Marion E. Scoggins, Jason B. White, Jennifer K. Litton, Vicente Valero, Kelly K. Hunt, Debu Tripathy, Wei Yang, Peng Wei, Clinton Yam, Mark D. Pagel, Gaiane M. Rauch, Jingfei Ma
Summary: Deep learning based on multiparametric MRI can potentially predict TNBC patients' pCR status in the breast early during NAST.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
He Dou, Siyuan Jia, Yuling Ba, Danli Luo, Pingyang Yu, Fucheng Li, Youyu Wang, Xingyan Chen, Min Xiao
Summary: This study analyzed the clinicopathological characteristics and chemotherapeutic response of patients with postpartum breast cancer (PPBC). The results showed that PPBC patients were younger, more likely to undergo breast-conserving surgery, and more likely to achieve pathological complete remission (pCR). PPBC was found to be an independent predictor of pCR attainment in breast cancer patients and demonstrated higher sensitivity to chemotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Judy C. Boughey, Tanya L. Hoskin, Courtney N. Day, Matthew P. Goetz
Summary: This study aimed to evaluate the association between genomic risk and nodal pCR in patients with ER+/HER2- breast cancer. The results showed a negative correlation between genomic risk and nodal pCR, with the highest rates observed in patients aged below 50 with high genomic risk.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Sara P. Myers, Gillian M. Ahrendt, Joanna S. Lee, Jennifer G. Steiman, Atilla Soran, Ronald R. Johnson, Priscilla F. McAuliffe, Emilia J. Diego
Summary: The study revealed that breast pCR and ypN0 primarily occurred in HER2+ and TNBC subtypes, and factors such as age, tumor subtype, and clinical stage were associated with ypN0. The impact of cN status on ypN0 varied among different tumor subtypes.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Andre Pfob, Chris Sidey-Gibbons, Geraldine Rauch, Bettina Thomas, Benedikt Schaefgen, Sherko Kuemmel, Toralf Reimer, Markus Hahn, Marc Thill, Jens-Uwe Blohmer, John Hackmann, Wolfram Malter, Inga Bekes, Kay Friedrichs, Sebastian Wojcinski, Sylvie Joos, Stefan Paepke, Tom Degenhardt, Joachim Rom, Achim Rody, Marion van Mackelenbergh, Maggie Banys-Paluchowski, Regina Grosse, Mattea Reinisch, Maria Karsten, Michael Golatta, Joerg Heil
Summary: Neoadjuvant systemic treatment is effective for breast cancer patients, but current nonsurgical methods cannot accurately identify patients without residual cancer. We developed an intelligent vacuum-assisted biopsy approach using machine learning algorithm, which can reliably exclude residual cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jieun Kim, Boo-Kyung Han, Eun Young Ko, Eun Sook Ko, Ji Soo Choi, Ko Woon Park
Summary: This study investigated the predictability of breast MRI for pathologic complete response (pCR) by molecular subtype in patients with breast cancer receiving neoadjuvant chemotherapy (NAC) and explored the MRI findings that can mimic residual malignancy. The results showed that the diagnostic accuracy of MRI for predicting pCR differed by molecular subtypes, and subtle residual enhancement observed on MRI after NAC was associated with false-negative findings.
EUROPEAN RADIOLOGY
(2022)
Article
Oncology
Frederik Knude Palshof, Charlotte Lanng, Niels Kroman, Cemil Benian, Ilse Vejborg, Anne Bak, Maj-Lis Talman, Eva Balslev, Tove Filtenborg Tvedskov
Summary: The study found that MRI was more specific than US in predicting pCR in breast cancer patients receiving NACT, but not specific enough to be a valid predictor for omitting surgery. MRI should be preferred for future studies on predicting pCR in NACT patients.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Jung Hwan Ji, Soong June Bae, Seul-Gi Kim, Min Hwan Kim, Gun-Min Kim, Joohyuk Sohn, Joon Jeong, Jee Hung Kim, Sung Gwe Ahn
Summary: This study investigated the impact of different doses of carboplatin on pathologic complete response rate, grade 3/4 anaemia occurrence, and transfusion rate in patients treated with neoadjuvant TCHP. The results showed that carboplatin at AUC5 has comparable cytotoxic effects to carboplatin at AUC6 and is associated with fewer complications related to anaemia in HER2+ breast cancer patients.
Article
Oncology
Shin-Cheh Chen, Chi-Chang Yu, Hsien-Kun Chang, Yung-Chang Lin, Yung-Feng Lo, Shih-Che Shen, Wen-Lin Kuo, Hsiu-Pei Tsai, Hsu-Huan Chou, Chia-Hui Chu, Wen-Chi Shen, Ren-Chin Wu, Shir-Hwa Ueng, Yi-Ting Huang
Summary: This study analyzed the differences in breast pathologic complete response (B-pCR) and axillary node pCR (N-pCR) rates in different intrinsic subtypes of early breast cancer after neoadjuvant chemotherapy (NAC). They found that N-non pCR or T-non pCR patients had the worst outcomes.
Article
Oncology
Ji-Yeon Kim, Eunjoo Jeon, Soonhwan Kwon, Hyungsik Jung, Sunghoon Joo, Youngmin Park, Se Kyung Lee, Jeong Eon Lee, Seok Jin Nam, Eun Yoon Cho, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im
Summary: This study developed a machine learning model based on pretreatment clinical and pathological characteristics from EMR data to accurately predict pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. The model showed varying performance in predicting pCR across different molecular subtypes.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Liangcun Guo, Siyao Du, Si Gao, Ruimeng Zhao, Guoliang Huang, Feng Jin, Yuee Teng, Lina Zhang
Summary: This study investigates the value of delta-radiomics after the first cycle of neoadjuvant chemotherapy (NAC) using dynamic contrast-enhanced (DCE) MRI for early prediction of pathological complete response (pCR) in patients with breast cancer. The results show that the delta-radiomics model based on early phases of DCE-MRI can effectively predict pCR in breast cancer patients. This model provides strong support for clinical decision-making and helps patients benefit the most from NAC.
Article
Oncology
Sara P. Myers, Varadan Sevilimedu, Andrea V. Barrio, Audree B. Tadros, Anita Mamtani, Mark E. Robson, Monica Morrow, Minna K. Lee
Summary: This study compared the pathologic complete response (pCR) between BRCA1/2 mutation carriers and sporadic breast cancer patients, and found that BRCA1 mutation carriers had a higher rate of pCR and may derive greater benefit from chemotherapy.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Aradhya Nigam, Jason S. Hawksworth, Emily R. Winslow
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mignote Yilma, Neil Mehta
Summary: Liver transplantation (LT) remains the optimal treatment for hepatocellular carcinoma (HCC), but considerations must be given to organ availability and risk of recurrence. In the United States, Milan criteria have been used to maximize the benefit of LT compared to alternative treatments. Advances in local regional therapy (LRT) have allowed us to downstage patients to meet Milan criteria, and newer selection criteria incorporating biomarkers and imaging are being developed to further optimize LT for HCC patients.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anthony Bejjani, Richard S. Finn
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Ifrah Fatima, Neehar D. Parikh, Alisa Likhitsup
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria Chernyak
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Gloria Y. Chang, Adam C. Yopp
Summary: HCC is the third leading cause of cancer-related deaths worldwide and its prognosis is complex and diverse, requiring consideration of tumor burden, biology, liver function, and patient status in treatment decision-making.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mikin Patel, Anjana Pillai
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Zachary Whitham, David Hsiehchen
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mariana Chavez-Villa, Ismael Dominguez-Rosado
Summary: Over the past 40 years, multiple staging systems have been developed for hepatocellular carcinoma (HCC) to guide treatment and determine prognosis. However, the heterogeneity of HCC and advances in diagnostic and therapeutic tools have made staging algorithms and eligibility criteria more complex. Recent advances in neoadjuvant therapy, downstaging, and adjuvant therapy have challenged traditional paradigms but also raised new questions. Although there is no perfect or universal staging system yet, models will continue to be refined as evidence advances. Individualized decision making and multidisciplinary approaches will play key roles in the management of HCC.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)